Canon, Jude

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 2,277

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 1,733

Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors

Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry

Protein Kinase Regulation and GTPase SignalingHeterocyclic Compound Synthesis and Bioactivity

Cited by 765

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery

Cell death mechanisms and regulationAcute Myeloid Leukemia Research

Cited by 432

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 290

The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents

Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 152

Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release

Zuch de Zafra, C. L., Fajardo, F., Zhong, W., Bernett, M. J., Muchhal, U. S., Moore, G. L., Stevens, J., Case, R., Pearson, J. T., Liu, S., et al. (2019) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 132

Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors

Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 82

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways

Saiki, A. Y., Caenepeel, S., Yu, D., Lofgren, J. A., Osgood, T., Robertson, R., Canon, J., Su, C., Jones, A., Zhao, X., et al. (2014) · Oncotarget

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 55

Small-molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors

Werner, L. R., Huang, S., Francis, D. M., Armstrong, E. A., Ma, F., Li, C., Iyer, G., Canon, J., & Harari, P. M. (2015) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysDNA Repair Mechanisms

Cited by 45